Investor Overview

Corporate Profile

vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Presentations

Date Title
More >>

Recent News

Date Title
Toggle Summary vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D HIGH POINT, N.C. , Sept. 23, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.
View HTML
Toggle Summary vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting
Potential First-in-Class, Liver-Selective Glucokinase Activator HIGH POINT, N.C. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced it will deliver two oral presentations emphasizing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes at
View HTML
Toggle Summary vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors
HIGH POINT, N.C. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) announced the appointment of Edward P. Taibi , Executive Vice President of MacAndrews & Forbes Incorporated (“MacAndrews”), to the vTv Board of Directors. Effective August 31, 2020 , Mr.
View HTML
Toggle Summary vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update
HIGH POINT, N.C. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2020 , and provided an update on the progress of its clinical programs. “Building on the successful phase 2 study completed earlier this
View HTML
Webcasts
More >>
Upcoming Events
More events are coming soon.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.